Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001992927 | SCV002235306 | uncertain significance | RASopathy | 2021-09-03 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with SOS1-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces aspartic acid with glutamic acid at codon 887 of the SOS1 protein (p.Asp887Glu). The aspartic acid residue is moderately conserved and there is a small physicochemical difference between aspartic acid and glutamic acid. |
Mayo Clinic Laboratories, |
RCV002261431 | SCV002541810 | uncertain significance | not provided | 2021-06-30 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002468366 | SCV002763279 | uncertain significance | Noonan syndrome 4 | criteria provided, single submitter | clinical testing | ||
Genome- |
RCV002468365 | SCV002763280 | uncertain significance | Fibromatosis, gingival, 1 | criteria provided, single submitter | clinical testing |